Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based concomitant therapy for refractory H. pylori
NCT05126121Unknown
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vonoprazan in Helicobacter pylori infection. Primary endpoint: Helicobacter pylori eradication rate at 6 months. Status: unknown.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05126121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126121.